Thanks Lodge for your support on this board. I br

Thanks Lodge for your support on this board. I brought up Dr Hirschs' consulting title because I had not understood his true position with OWCP. When he came on board he did state that he would be issuing reports twice a year, which at that time was better than what shareholders were being provided. It just seems that things are really getting dragged out longer, to the point that we get a yearly summary by Dr Hirsch. I don't preach to any choir, but having a consistent report by our chairman should be a requirement for his job, and as a consultant, the shareholders should be made aware of most all considerations being presented to the management teams. At what point will our small R&D company turn the corner and request help from others to improve shareholder awareness and morale? I'm sure Dr Hirsch has established some goals within each "clinical trial" before moving to a higher level - if so, what is it they are striving to reach? Howards trip was certainly the highlight of my 3 years supporting this company - and I feel may be at the halfway point on my investment( these next 3 years should be accelerated in terms of patent approvals, clinicals moving to higher levels, potential NASDAQ uplisting, and beginning revenue from sales.

I definitely agree with your last statement regarding legislators, FDA, and the MMJ industry and will add this. Dr Hirsch has parallel links with FOMX and their share price has been stagnant even through phase 3 and 4 clinicals. If their product has been ready for production for almost a year, received all approvals and nothing has happened, I can't overlook the fact that Dr Hirsch is also a responsible part of this company,too. His Doctorate is not in Business Administration. His expertise is in research. I'm hoping when OWCP"S research hits his clinical goals that he will have the decency, as a consultant, to recommend someone with business savvy and experience, to lead our company up the next leg of biopharma development, distribution, or joint venture negotiations.

Thanks again Lodge!